ANTIPODES PARTNERS Ltd
Position in GPCR — Structure Therapeutics Inc.
CIK 1652442
ROYAL EXCHANGE, C3
Position in GPCR
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$2,751,231
+$564,831 QoQ
Shares Held
51,262
+13.0% QoQ
Ownership
0.072%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#74
of 191 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GPCR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ANTIPODES PARTNERS Ltd holds $60,434,232 across 11 Biotechnology names. GPCR ranks #3 (4.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
163,533 | $49,228,338 | |
| 2 | HUMA |
Humacyte, Inc.
|
10,103,647 | $7,880,844 | |
| 3 | GPCR |
Structure Therapeutics Inc.
This page
|
51,262 | $2,751,231 | |
| 4 | ARGX |
Argenx SE
|
187 | $173,492 | |
| 5 | IMNM |
Immunome Inc.
|
7,971 | $168,905 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
235 | $116,731 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
379 | $36,944 | |
| 8 | TNGX |
Tango Therapeutics, Inc.
|
1,037 | $32,416 |
All Filings in GPCR
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,751,231 | 51,262 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $2,186,400 | 45,361 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $3,219,538 | 46,291 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $114,184 | 4,078 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $60,809 | 2,932 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $73,515 | 4,247 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $28,042 | 1,034 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $21,111 | 481 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $20,695 | 527 | Shares | Sole | 2024-08-05 | |
| No filing history on record for this holder in this stock. | ||||||